| __timestamp | Dynavax Technologies Corporation | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 22570000 |
| Thursday, January 1, 2015 | 22180000 | 24378000 |
| Friday, January 1, 2016 | 37257000 | 26621000 |
| Sunday, January 1, 2017 | 27367000 | 28653000 |
| Monday, January 1, 2018 | 64770000 | 37734000 |
| Tuesday, January 1, 2019 | 74986000 | 41884000 |
| Wednesday, January 1, 2020 | 79256000 | 64435000 |
| Friday, January 1, 2021 | 100156000 | 57483000 |
| Saturday, January 1, 2022 | 131408000 | 70062000 |
| Sunday, January 1, 2023 | 152946000 | 52790000 |
In pursuit of knowledge
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech firms: Ligand Pharmaceuticals Incorporated and Dynavax Technologies Corporation, from 2014 to 2023.
Over this period, Dynavax Technologies Corporation has seen a staggering 760% increase in SG&A expenses, peaking at approximately $153 million in 2023. This growth reflects the company's aggressive expansion and investment in administrative capabilities. In contrast, Ligand Pharmaceuticals Incorporated experienced a more modest 134% increase, reaching around $70 million in 2022, before a slight dip in 2023.
These trends highlight differing strategic approaches: Dynavax's rapid scaling versus Ligand's steady growth. Investors should consider these trajectories when evaluating potential opportunities in the biotech sector.
Selling, General, and Administrative Costs: Johnson & Johnson vs Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Biogen Inc. and Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing MorphoSys AG and Dynavax Technologies Corporation
Cost Management Insights: SG&A Expenses for Amicus Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: ImmunityBio, Inc. vs Dynavax Technologies Corporation
Soleno Therapeutics, Inc. vs Dynavax Technologies Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Dynavax Technologies Corporation and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Celldex Therapeutics, Inc.